The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function
Recruiting · NCT03240328 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
CAR-T cells
What this trial is about
To study the safety and effectiveness of CAR-T Cell therapy on HIV patients whose plasma HIV has been successfully suppressed after cART, which is expected to enhance the res-constitution of HIV-specific immune function to assist the eradication of HIV reservoir.
Who can take part
Age range
18 Years to 60 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- HIV infection confirmed.
- Receiving cART more than 12 months.
- HIV viral-load \< 50 copies/ml and CD4 cell count more than 350 cells/ul.
- Without serious liver, heart, liver and kidney diseases.
- The subjects know about the study and volunteer to attend the research and sign the informed consent.
Exclusion criteria
- With active HBV or HCV infection, or serious opportunistic infections.
- With serious chronic disease such like diabetes, the mental illness,et al
- History of suffering from pancreatitis during cART.
- Pregnant or breast-fed.
- With poor adherence.
- Unable to complete follow up.
Where it is running
1 location listed.
- Guangzhou 8th People's Hospital - Guangzhou, Guangdong, China